Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus MYCHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus MYCHEL.
CHLOROMYXIN vs MYCHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Adults: 200 mg orally twice daily for 14 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
CHLOROMYXIN is not a recognized drug. No data available.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Category C
Category C
Antibiotic
Antibiotic